

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
27 November 2003 (27.11.2003)

PCT

(10) International Publication Number
WO 03/097073 A1(51) International Patent Classification⁷: **A61K 31/726**,
45/06, A61P 29/00 // (A61K 31/726, 31:135) (A61K
31/726, 31:167)

(21) International Application Number: PCT/DK03/00263

(22) International Filing Date: 22 April 2003 (22.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2002 00586 19 April 2002 (19.04.2002) DK
60/373,615 19 April 2002 (19.04.2002) US(71) Applicant (for all designated States except US): **AS-
TION DEVELOPMENT A/S** [DK/DK]; Fruebjergvej 3,
DK-2100 Copenhagen Ø (DK).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **WEIDNER, Morten**,
Sloth [DK/DK]; Solbakken 7, DK-2830 Virum (DK).(74) Agent: **Plougmann - Vingtoft a/s**; Sundkrogsgade 9,
P.O.Box 831, DK-2100 Copenhagen Ø (DK).(81) Designated States (*national*): AE, AG, AL, AM, AT (util-
ity model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (util-
ity model), DE, DK (utility model), DK, DM, DZ, EC, EE
(utility model), EE, ES, FI (utility model), FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*(54) Title: COMBINATION OF A BETA-2 ADRENOCEPTOR AGONISTS AND AN AMINOSUGARS AND THEIR USE FOR
THE TREATMENT IMMUNOMODULATORY DISORDERS(57) Abstract: The invention relates to combinations of an aminosugar and a beta-2 adrenoceptor agonist, such as salbutamol, for the
treatment of diseases associated with hypersensitivity and inflammation, in particular hypersensitivity skin diseases. The aminosugar
is preferably a monosaccharide derivative.

WO 03/097073 A1

COMBINATION OF A BETA-2 ADRENOCEPTOR AGONIST AND AN AMINOSUGAR AND THEIR USE FOR THE TREATMENT OF IMMUNOMODULATORY DISORDERS

FIELD OF THE INVENTION

The present invention relates to the combination of a beta-2 adrenoceptor agonist and an
5 aminosugar suitably formulated in the form of a chemical complex and/or a pharmaceutical
composition for the suppression and treatment of hypersensitivity and inflammatory
reactions in mammals.

BACKGROUND OF THE INVENTION

10 A number of drug classes are available for the treatment of hypersensitivity and
inflammatory reactions. Among these, the corticosteroids are some of the most widely and
effective drugs used. Corticosteroids primarily exert their pharmacological action by non-
selectively inhibiting the function and proliferation of different classes of immune cells
resulting in suppression of hypersensitivity and inflammatory reactions. Unfortunately, the
15 corticosteroids are associated with a number of serious side effects, e.g. immuno-
suppression, osteoporosis and skin atrophy.

Non-steroidal anti-inflammatory drugs are another class of drugs extensively used in the
treatment of hypersensitivity and inflammatory reactions. Also this class of drugs is
20 associated with serious side effects, in particular upon long-term use.

Hypersensitivity is defined as a state of altered reactivity in which the body reacts with an
exaggerated immune response to a substance (antigen).

25 Hypersensitivity reactions underlie a large number of diseases. Among these, allergic and
autoimmune conditions are of great importance. A classification of hypersensitivity
diseases is given in the textbook Clinical Medicine (Kumar, P. and Clark, M.: "Clinical
Medicine", 3rd edition, p. 147-150, 1994, Bailliere Tindall, London). Hypersensitivity may
be classified as type I hypersensitivity reactions (IgE mediated allergic reactions) which is
30 known to play a significant role include asthma, eczema (atopic dermatitis), urticaria,
allergic rhinitis and anaphylaxis. Type II hypersensitivity reactions are caused by cell
surface or tissue bound antibodies (IgG and IgM) and play a significant role in the
pathogenesis of myasthenia gravis, Good-pasture's syndrome and Addisonian pernicious
anaemia. Type III hypersensitivity reactions (immune complex) are caused by
35 autoantigens or exogenous antigens, such as certain bacteria, fungi and parasites.

Diseases in which type III hypersensitivity reactions play a significant role include lupus erythematosus, rheumatoid arthritis and glomerulonephritis. Type IV hypersensitivity reactions (delayed) are caused by cell or tissue bound antigens. This type of hypersensitivity plays a significant role in a number of conditions, e.g. graft-versus-host disease, leprosy, contact dermatitis and reactions due to insect bites.

In addition cancer may be regarded as a condition associated with hypersensitivity reactions. Cancer is caused by an uncontrolled proliferation of cells that express varying degrees of fidelity to their precursors. These cancer cells form a malignant tumour that enlarges and may spread to adjacent tissues or through blood and lymph systems to other parts of the body. There are numerous forms of cancer of varying severity. For most types of cancer there is no effective treatment today.

Generally, the treatment of hypersensitivity and inflammatory diseases, including cancer, requires long-term administration. Thus, there is a need for therapeutic agents for the treatment of hypersensitivity and inflammatory reactions, including cancer, in particular agents that have a better safety profile than presently available drugs.

Aminosugars are generally recognised as having beneficial effect on inflammatory reactions. Aminosugars are the building blocks for the *in vivo* generation of glycosaminoglycans, formerly known as mucopolysaccharides. Glycosaminoglycans are constituents in various tissues in numerous mammals, both vertebrates and invertebrates and as such not likely to be associated with adverse reactions upon administration to mammals. Important examples of glycosaminoglycans are chondroitin sulfates, keratan sulfates in connective tissue, dermatan sulfates in skin tissue and hyaluronic acid in skin tissue and synovial joint fluid.

Administration of aminosugars or glycosaminoglycans in high (pharmacological) doses to individuals suffering from osteoarthritis has resulted in some relief of symptoms and nowadays the use of aminosugars as chondroprotective agents is widely recognised (*Gaby AR, Natural treatments for osteoarthritis, Alternative medicine review, volume 4, No 5, 1999, pages 330-334*). For example, the use of aminosugars and glycosaminoglycans for reducing inflammation is mentioned in WO 98/48816. US 6.046,179 relates to the treatment of inflammatory bowel diseases by colonic administration of N-acetylglucosamine.

Sympathomimetics are drugs that partially or completely mimic the actions of noradrenaline or adrenaline. They act either directly on alpha- and/or beta-adrenoceptors or indirectly on the presynaptic terminals usually by causing the release of noradrenaline.

The effects of adrenoceptor stimulation are various. Beta-2 adrenoceptor agonists are a class of drugs known to provide bronchodilation and are widely used in the treatment of asthma. WO 95/19336 relates to phenyl ethanol amine ethers for use as a beta-2 adrenoceptor agonists in bronchitis, allergic bronchitis and asthma bronchiale.

EP 069042 relates to drug compositions comprising a mucopolysaccharide and a drug which is scarcely soluble in water but soluble in a water-miscible organic solvent, such as salbutamol. The drug is present as fine crystals or fine particles attached on or between the particles of a mucopolysaccharide.

SUMMARY OF THE INVENTION

It has been found by the present investigator that a combination of a beta-2 adrenoceptor agonist and an aminosugar significantly suppresses hypersensitivity and inflammatory reactions.

Contrarily to existing therapeutic agents, such as corticosteroids or non-steroidal anti-inflammatory drugs, the chemical complexes and compositions according to the present invention have the advantage of not being likely to be associated with any serious side effects, as all of their components are known to living organisms and are acknowledged reported as non-toxic and well-tolerated by the organism. The present inventor puts forward the hypothesis that the very beneficial therapeutic index exhibited by the complex and compositions comprising said complex according to the invention is superior to the use of the individual constituents of the complex, and this is due to synergistic effects and a lower toxic load on the organism.

Such a combination is advantageously provided in the form of a chemical complex comprising a beta-2 adrenoceptor agonist and an aminosugar. Obviously, the combination may also be provided in the form of a pharmaceutical composition, a dietary supplement or a cosmetic. As was further recognised by the present inventor, the aminosugar according to the present invention may be an aminosugar derivative of monosaccharides, oligosaccharides as well as of polysaccharides. However, the aminosugar may advantageously have a molecular weight of less than 5000.

Thus, the present inventor has recognised the therapeutic activity of a combination of beta-2 adrenoceptor agonist and an aminosugar, for which reason the said combination may be regarded as an active therapeutic agent.

Accordingly, the present invention provides a chemical complex or a pharmaceutical composition comprising:

- i) a beta-2 adrenoceptor agonist; and
- ii) an aminosugar; and optionally.
- 5 iii) a pharmaceutically acceptable carrier or carrier.

The chemical complexes and pharmaceutical compositions according to the invention may in general be utilised in the treatment of diseases associated with hypersensitivity and inflammatory reactions. In general the combination may be utilised in i) immuno-

10 modulation, and in more specific terms they may be utilised in ii) the treatment or prevention of hypersensitivity diseases such as atopic eczema, contact dermatitis, seborrhoeic eczema and/or psoriasis; ii) the treatment or prevention of IgE mediated allergic reactions and conditions such as of asthma, allergic rhinitis, and/or anaphylaxis; iv) the treatment or prevention of autoimmune disorders such as of diabetes, Crohn's

15 disease, ulcerative colitis, rheumatoid arthritis, gout or osteoarthritis; v) the alleviation of pain; vi) the treatment or prevention of cancer.

An important aspect of the invention relates to the use of a combination of a beta-2 adrenoceptor agonist and an aminosugar for the preparation of a product for the treatment

20 of diseases i) to vi) as mentioned above.

Still further aspects relate independently to a method for treating diseases i) to vi) as mentioned above in a mammal, such as a human, comprising the administration of a combination of a beta-2 adrenoceptor agonist and an aminosugar, pharmaceutically

25 acceptable salts thereof, or a complex comprising said combination or said salts to said mammal.

Moreover, a still further aspect of the invention relates to a process for the preparation of a complex comprising i) a beta-2 adrenoceptor agonist; and ii) an aminosugar, comprising

30 the steps of:

- i) dissolving said beta-2 adrenoceptor and said aminosugar in a volatile solvent or a mixture of volatile solvents; and
- ii) removing said suitable solvent so as to obtain a moisture content of at the most 5% w/w.

DETAILED DESCRIPTION OF THE INVENTION

The present inventor provides data herein indicating that a combination of a beta-2 adrenoceptor agonist and an aminosugar significantly reduces the inflammation in the arachidonic acid ear inflammation test in mice. This reduction of inflammation was better
5 for the combination than for each of the individual compounds and also far better than that obtained by a commonly used steroid.

It is hypothesised by the present inventor that the very advantageous therapeutic index of the combination of a beta-2 adrenoceptor agonist and an aminosugar in comparison to
10 each of the singular components is due to synergistic effects between the components of the compositions. Advantageously, this allows for the utility of lower dosages, while yet providing a surprisingly good therapeutic effect.

The invention is based, at least in part, on the combined activity of an aminosugar and a
15 beta-2 adrenoceptor agonist in comparison to either component. This combined activity allows for the use of beta-2 adrenoceptor agonists that are previously not used as therapeutic agents because they were too toxic in therapeutically relevant doses or because high doses were required in order to achieve said effect.

20 According to the invention, the combination of a beta-2 adrenoceptor agonist and an aminosugar may be provided in the form of a chemical complex; in the form of a composition comprising said complex and optionally pharmaceutically acceptable excipient(s); or in the form of a pharmaceutical composition comprising the combination of beta-2 adrenoceptor agonist and an aminosugar.

25 Without being limited to a particular theory, advantageously, said combination is provided in the form of a chemical complex for purposes of achieving a homogeneous mixture of the two agents, which may positively affect the resulting therapeutic effect.

30 Such chemical complexes are novel and provide a surprisingly effective anti-hypersensitivity and anti-inflammatory effect with a surprisingly good safety profile. Thus the chemical complexes or compositions of the invention are virtually non-toxic at active doses and yet very therapeutically effective.

35 The chemical complexes or compositions of the invention provide pharmacological effects upon administration to the living organism such as immunomodulation, suppression of hypersensitivity reactions, suppression of IgE mediated allergic reactions, suppression of autoimmune reactions, reduction of pain, and suppression of cancer.

Accordingly, the present invention relates to a chemical complex comprising:

- i) a beta-2 adrenoceptor agonist; and
- ii) an aminosugar.

5 The term "chemical complex" is intended to include the definition defined by IUPAC that read as follows:

"A molecular entity formed by loose association involving two or more component molecular entities (ionic or uncharged), or the corresponding chemical species. The bonding between the components is normally weaker than in a covalent bond." (IUPAC

10 *Compendium of Chemical Terminology 2nd Edition (1997)*)

Thus, the term "chemical complex" is intended to mean any combination of the components provided that the molecules of each of the components are mixed and loosely associated with each other. The term "chemical complex" is not intended necessarily to
15 imply an ionic or otherwise association between the components. It does not either include covalent bonding between the components of the complex. Moreover, the term "chemical complex" does not encompass combinations wherein one or both of the components are in the form of particles. However, a chemical complex of the invention may not be 100 % pure in that some of the components may be present in the form of
20 particles. That is to say that preferably less than 10% of each of the components are in the form of particles in a chemical complex. More preferably less than 5%, less than 2.5% or less than 1% is in particulate matter. Thus, a composition or a chemical complex according to the invention may comprise less than 10% of one of the components in the form of particulate matter.

25

The complexes of the invention may be prepared according to a number of different methods, which are obvious to a person skilled in the art. The following procedures are non-limiting examples of such methods:

The components of the complex, dosed in appropriate amounts to give the correct molar
30 ratio between the components, are dissolved, dispersed, or suspended in an appropriate solvent, for example water, an organic solvent or mixtures thereof. Non-limiting examples of suitable organic solvents are ethanol, methanol, *iso*-propyl alcohol, acetone, hexane, ethylacetate or mixtures thereof.

The solvent is then removed by a technique suitable for the complex, for example but not
35 limited to evaporation, *in vacuo* evaporation, spray drying, freeze-drying, fluid bed drying or spin flash drying. Alternatively, the complex may be obtained by precipitation and subsequent centrifugation or filtering.

In the present context, the term "aminosugar" is intended to mean one or more amino derivatives of a monosaccharide (aldoses and ketoses) and its corresponding sugar alcohols (alditols) such as trioses, tetroses, pentoses, hexoses, heptoses and octoses. The aldose, ketose, or alditol has one or more hydroxy groups replaced by any amino group at any position, including the anomeric position. An aminosugar is thus a deoxyamino derivative of an aldose, ketose, or alditol. The term is also intended to mean polyamino sugars, wherein more than one hydroxy group has been replaced by an amino group (e.g. dideoxydiamino-, trideoxytriamino-derivatives).

Moreover, the term "aminosugar" is also intended to mean amino derivatives of di-, oligo- and poly-saccharides comprising at least one of said monosaccharides. Consequently, in the case of di-, oligo- and poly-saccharides, the amino group may be the position of glycosidation. Suitably, in di-, oligo- and poly-saccharides, the amino group may not be the position of glycosidation.

An amino group of an aminosugar may be alkylated, arylated or acylated or, alternatively, present as its free amine form (NH_2). Similarly, the hydroxyl groups may be optionally protected or derivatised such as alkylated, arylated or acylated or, alternatively, present in its free hydroxyl form.

The amine of the amino sugar may exist as its quaternary ammonium salt using organic or mineral acids, as is known to the person skilled in the art. Furthermore, other functional groups on the aminosugar may be in the form of a salt. Similarly, prodrug derivatives of the aminosugar are anticipated by the present inventor. The prodrug form may be the result of the derivatisation of the amino group or another functional group present on the aminosugar, as is known to the person skilled in the art.

Furthermore, an aminosugar may have one or more hydroxy groups replaced by any amino group at any position and a further one or more hydroxy groups replaced by a hydrogen (a deoxy sugar), a thiol (a thiosugar), a halogen (a deoxyhalo sugar), an anhydrosugar (a sugar preparable via an intramolecular displacement with a hydroxyl to form an oxirane or oxetane), a carbonyl group.

Furthermore, the term aminosugar is denoted to mean aminosugars as described *supra* but optionally substituted.

The term "optionally substituted" is intended to mean the substitution of one or more hydrogen atoms, which is substituted with another atom, chemical group or entity, termed substituents. Illustrative examples of substituents include carboxyl, formyl, amino,

hydroxyl, halogen, nitro, sulphono, sulphanyl, C₁₋₆-alkyl, aryl, aryloxy, aryloxycarbonyl, arylcarbonyl, heteroaryl, amino, mono- and di(C₁₋₆-alkyl)amino; carbamoyl, mono- and di(C₁₋₆-alkyl)aminocarbonyl, amino-C₁₋₆-alkyl-aminocarbonyl, mono- and di(C₁₋₆-alkyl)amino-C₁₋₆-alkyl-aminocarbonyl, C₁₋₆-alkylcarbonylamino, cyano, guanidino, carbamido, C₁₋₆-alkanoyloxy, C₁₋₆-alkylsulphonyloxy, dihalogen-C₁₋₆-alkyl, trihalogen-C₁₋₆-alkyl, C₁₋₆-alkoxyl, oxo, C₁₋₆-carboxyl, C₁₋₆-alkoxycarbonyl, C₁₋₆-alkylcarbonyl, where aryl and heteroaryl representing substituents may be substituted 1-5 times with C₁₋₆-alkyl, C₁₋₆-alkoxy, nitro, cyano, hydroxy, amino or halogen. In general, the above substituents may be susceptible to further optional substitution.

10

The term "halogen" includes fluorine, chlorine, bromine and iodine.

In a particularly suitable embodiment of the invention, the aminosugar is sulphated or phosphorylated at the anomeric, 2-, 3-, 4-, or 6- position, typically at the 2-, 3-, or 4-
15 position. In another suitable embodiment of the invention the aminosugar is N-acetylated.

Furthermore, a combination of suitable embodiments include the aminosugar sulphated or phosphorylated as well as in its salt form having Na⁺; K⁺; Mg⁺⁺; Ca⁺⁺; or NH₄⁺ as counter ions.

20

Particularly suitable aminosugars according to the invention are amino derivatives of monosaccharides selected from the group consisting of glucosamine, galactosamine and mannosamine, derivatives and salts thereof. Typically, the amino derivatives of monosaccharides may be in the form of salts, such as the sulfate salt and hydrochloride
25 salts, or N-acetylated, e.g. glucosamine sulfate, glucosamine hydrochloride, N-acetylglucosamine, galactosamine sulfate, galactosamine hydrochloride, N-acetylgalactosamine, mannosamine sulfate, mannosamine hydrochloride, N-acetylmannosamine, as well as other aminosugars known to the person skilled in the art.

30 In suitable embodiments the aminosugar is di-, oligo-, and poly-saccharides comprising at least one or more of the mentioned amino derivatives of monosaccharides. In the embodiment wherein the aminosugar is an oligo- or polysaccharide, said oligo- or polysaccharide preferably contain monomeric sugars including D-glucuronic acid, L-iduronic acid, D-galacturonic acid, D-galactose, and fucose, each of which may be
35 optionally sulfonated or O-substituted with a protective group known to the person skilled in the art.

In a suitable embodiment of the invention, the chemical complex and the composition comprises more than one aminosugar.

Preferably, the aminosugar is an amino derivate of a monosaccharide as mentioned *supra*. In the embodiment wherein the aminosugar is oligo- and poly-saccharides the molecular weight is preferably less than 5000 Daltons, preferably less than 4000 Daltons, more

5 preferably less than 3000 Daltons

The aminosugar component of the invention may comprise natural, synthetic or semisynthetic aminosugars and may have been chemically modified, while still retaining their function. Such chemical modifications include but are not limited to esterification,

10 sulfation, polysulfation, acetylation and methylation.

As stated, the invention relates to the combination of an aminosugar with a beta-2 adrenoceptor agonist. The term "beta-2 adrenoceptor agonist" is intended to mean any component with the ability to stimulate a beta-2 adrenoceptor or parts thereof. The

15 agonistic activity of a compound towards beta-2 adrenoceptor may be investigated by methods known to the person skilled in the art, eventually using salmeterol as reference. Preferably, the beta-2 adrenoceptor agonist may be any that possess at least 10% of the activity of salmeterol in a suitable test for beta-2 adrenoceptor agonism. Preferably, the beta-2 adrenoceptor agonist has at least 20%, more preferably at least 40% such as at

20 least 50%, 60%, 75%, 80%, 85%, 90% of the activity of salmeterol in a suitable test for beta-2 adrenoceptor agonism.

The beta-2 adrenoceptor agonist, for illustrative purposes, may be selected from the group consisting of bambuterol, bitolterol, carbuterol, clenbuterol, clorprenaline, dioxethedrine,

25 dopexamine, ephedrine, epinephrine, etafedrine, ethylnorepinephrine, fenoterol, formoterol, hexoprenaline, isoetarine, isoproterenol, mabuterol, metaproterenol, methoxyphenamine, pirbuterol, procaterol, protokylol, reproterol, rimiterol, ritodrine, salbutamol (albuterol), salmeterol, soterenol, terbutaline, tretoquinol, tulobuterol, derivatives, salts and enantiomeres thereof.

30

In interesting embodiments the beta-2 adrenoceptor agonist is terbutaline sulfate, salbutamol sulfate or formoterol fumarate dihydrate.

According to the invention the beta-2 adrenoceptor agonist may preferably be in the form

35 of the most effective single enantiomer or optimal mixtures of enantiomers as known to a person skilled in the art.

As stated the combination of the two agents provides a surprisingly effective therapeutic agent for suppression of hypersensitivity and inflammatory reactions. The proper

therapeutic efficacy may, in part, be adjusted by providing the two agents in suitable molar ratios or mass ratios.

The molar ratio between the beta-2 adrenoceptor agonist and the aminosugar may be
5 about 1:10000 to 10000:1, preferably about 1:1000 to 1000:1, such as about 1:500 to 500:1, such as 1:100 to 100:1, about 1:50 to 50:1, or about 1:40 to 40:1, also about 1:30 to 30:1, such as about 1:25 to 25:1, about 1:20 to 20:1, about 1:18 to 18:1, about 1:16 to 16:1, about 1:14 to 14:1, or about 1:12 to 1:12, also about 1:10 to 10:1, such as about 1:9 to 9:1, about 1:8 to 8:1, about 1:7 to 7:1, about 1:6 to 6:1, also from 1:5 to
10 5:1, such as from 1:4 to 4:1, e.g. from 1:3 to 3:1, such as from 1:2 to 2:1.

Alternatively defined, the ratio between the beta-2 adrenoceptor agonist and the aminosugar may be expressed as a mass ratio. The mass ratio between the beta-2 adrenoceptor agonist and the aminosugar may be about 1:10000 to 10000:1, preferably
15 about 1:1000 to 1000:1, such as about 1:500 to 500:1, such as 1:100 to 100:1, about 1:50 to 50:1, or about 1:40 to 40:1, also about 1:30 to 30:1, such as about 1:25 to 25:1, about 1:20 to 20:1, about 1:18 to 18:1, about 1:16 to 16:1, about 1:14 to 14:1, or about 1:12 to 1:12, also about 1:10 to 10:1, such as about 1:9 to 9:1, about 1:8 to 8:1, about 1:7 to 7:1, about 1:6 to 6:1, also from 1:5 to 5:1, such as from 1:4 to 4:1, e.g. from 1:3
20 to 3:1, such as from 1:2 to 2:1.

For the administration to a mammal, such as a human, the chemical complex may be administered directly, eventually provided in a capsule or the like. More convenient, the complex may be formulated into a composition comprising the chemical complex and
25 optionally, one or more acceptable excipients. Alternatively, the combination of the two agents may also be formulated into a composition without being provided as a chemical complex.

Thus, an important aspect of the present invention relates to a composition comprising:

- 30 i) a beta-2 adrenoceptor agonist;
ii) an aminosugar; and optionally
iii) one or more acceptable excipients or carriers.

It is to be understood that the "beta-2 adrenoceptor agonist" and the "aminosugar" of the
35 composition are as defined *supra*. In one embodiment, the composition comprises the combination of beta-2 adrenoceptor agonist and the aminosugar in the form of a chemical complex as defined herein. Thus, the aminosugar may be selected from the group consisting of glucosamine, galactosamine, mannosamine, derivatives and salts thereof, e.g. wherein the aminosugar is N-acetylglucosamine, N-acetylgalactosamine or N-

acetylmannosamine. A preferred composition comprises glucosamine sulfate, glucosamine hydrochloride and/or N-acetylglucosamine. Moreover, the molar ratio or mass ratio between the beta-2 adrenoceptor agonist and the aminosugar in the composition may be as defined for the complex, as discussed *supra*.

5

The term "composition" is intended to mean cosmetic compositions, pharmaceutical compositions, nutritional compositions such as food supplements as well as compositions in the field of cosmeceuticals and nutraceuticals.

10 According to the invention, the above-mentioned chemical complexes or compositions may be combined with any other therapeutically active agents in order to strengthen, improve, potentiate, or prolong the therapeutic actions of said complexes and said compositions. Thus according to the invention, the composition or complexes may further comprise one or more therapeutically active agents.

15

The compositions according to the present invention may be formulated for oral, topical, transdermal, or parenteral administration, preferably oral or topical administration.

In a suitable embodiment of the invention, the compositions are used for oral administration. In another suitable embodiment of the invention the compositions are used

20 for topical administration.

The beta-2 adrenoceptor agonist and the aminosugar may together be comprised in a single formulation or may each individually be comprised in separate formulations. The separate formulations may be administered in a simultaneous or non-simultaneous

25 manner. As stated, the beta-2 adrenoceptor agonist and the aminosugar are together comprised in a single formulation.

The active ingredients of the chemical complex or pharmaceutical composition of the present invention need not be administered as one pharmaceutical entity, but may of course be administered as individual compounds or pharmaceutical compositions.

30 In addition to the formulations described previously, the compositions of the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compositions may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable
35 oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

The pharmaceutical compositions for oral, topical, transdermal, or parenteral administration may be in form of, e.g., solid, semi-solid or fluid compositions and formulated according to conventional pharmaceutical practice, see, e.g., "Remington: The science and practice of pharmacy" 20th ed. Mack Publishing, Easton PA, 2000 ISBN 0-

- 5 912734-04-3 and "Encyclopedia of Pharmaceutical Technology", edited by Swarbrick, J. & J. C. Boylan, Marcel Dekker, Inc., New York, 1988 ISBN 0-8247-2800-9.

The choice of pharmaceutically acceptable excipients in a composition for use according to the invention and the optimum concentration thereof is determined on the basis of the

- 10 selection of the beta-2 adrenoceptor agonist, selection of the aminosugar, the kind of dosage form chosen and the mode of administration. However, a person skilled in the art of pharmaceutical formulation may find guidance in e.g., "Remington: The science and practice of pharmacy" 20th ed. Mack Publishing, Easton PA, 2000 ISBN 0-912734-04-3. A pharmaceutically acceptable excipient is a substance, which is substantially harmless to
- 15 the individual to which the composition will be administered. Such an excipient suitably fulfils the requirements given by the national drug agencies. Official pharmacopeias such as the British Pharmacopeia, the United States of America Pharmacopeia and the European Pharmacopeia set standards for well-known pharmaceutically acceptable excipients.

- 20 For topical, trans-mucosal and trans-dermal compositions, such as administration to the mucosa or the skin, the compositions for use according to the invention may contain conventional non-toxic pharmaceutically acceptable carriers and excipients including microspheres and liposomes.

- 25 The topical, trans-mucosal and trans-dermal compositions for use according to the invention include an array of solid, semi-solid and fluid compositions. Compositions of particular relevance are e.g. pastes, ointments, hydrophilic ointments, creams, gels, hydrogels, solutions, emulsions, suspensions, lotions, liniments, resorbibles, suppositories, enema, pessaries, moulded pessaries, vaginal capsules, vaginal tablets, shampoos, jellies,
- 30 soaps, sticks, sprays, powders, films, foams, pads, sponges (e.g. collagen sponges), pads, dressings (such as, e.g., absorbent wound dressings), drenches, bandages, plasters and transdermal delivery systems.

The pharmaceutically acceptable excipients for topical, trans-mucosal and trans-dermal

35 compositions may include solvents, buffering agents, preservatives, humectants, chelating agents, antioxidants, stabilizers, emulsifying agents, suspending agents, gel-forming agents, ointment bases, suppository bases, penetration enhancers, perfumes, skin protective agents, diluents, disintegrating agents, binding agents, lubricants and wetting agents.

The oral compositions for use according to the invention include an array of solid, semi-solid and fluid compositions. Compositions of particular relevance are e.g. solutions, suspensions, emulsions, uncoated tablets, immediate-release tablets, modified-release
5 tablets, gastro-resistant tablets, orodispersible tablets, effervescent tablets, chewable tablets, soft capsules, hard capsules, modified-release capsules, gastro-resistant capsules, uncoated granules, effervescent granules, granules for the preparation of liquids for oral use, coated granules, gastro-resistant granules, modified-release granules, powders for oral administration and powders for the preparation of liquids for oral use.

10

The pharmaceutically acceptable excipients may include solvents, buffering agents, preservatives, humectants, chelating agents, antioxidants, stabilizers, emulsifying agents, suspending agents, gel-forming agents, diluents, disintegrating agents, binding agents, lubricants, coating agents and wetting agents.

15

Typical solvents may be selected from the group comprising water, alcohols, vegetable or marine oils (e.g. edible oils like almond oil, castor oil, cacao butter, coconut oil, corn oil, cottonseed oil, linseed oil, olive oil, palm oil, peanut oil, poppyseed oil, rapeseed oil, sesame oil, soybean oil, sunflower oil, and teaseed oil), mineral oils, fatty oils, liquid
20 paraffin, polyethylene glycols, propylene glycols, glycerol, liquid polyalkylsiloxanes, and mixtures thereof.

Typical buffering agents may be selected from the group comprising of citric acid, acetic acid, tartaric acid, lactic acid, hydrogenphosphoric acid, diethylamine etc.

25

Typical preservatives may be selected from the group comprising parabens, such as methyl, ethyl, propyl p-hydroxybenzoate, butylparaben, isobutylparaben, isopropylparaben, potassium sorbate, sorbic acid, benzoic acid, methyl benzoate, phenoxyethanol, bronopol, bronidox, MDM hydantoin, iodopropynyl butylcarbamate, EDTA,
30 benzalconium chloride, and benzylalcohol, or mixtures of preservatives.

Typical humectants may be selected from the group comprising glycerin, propylene glycol, sorbitol, lactic acid, urea, and mixtures thereof. Typical chelating agents are but not limited to sodium EDTA and citric acid. Typical antioxidants may be selected from the
35 group comprising butylated hydroxy anisole (BHA), ascorbic acid and derivatives thereof, tocopherol and derivatives thereof, cysteine, and mixtures thereof. Suitable emulsifying agents may be selected from the group comprising naturally occurring gums, e.g. gum acacia or gum tragacanth; naturally occurring phosphatides, e.g. soybean lecithin; sorbitan

monooleate derivatives; wool fats; wool alcohols; sorbitan esters; monoglycerides; fatty alcohols, fatty acid esters (e.g. triglycerides of fatty acids); and mixtures thereof.

Suitable suspending agents may be selected from the group comprising celluloses and
5 cellulose derivatives such as, e.g., carboxymethyl cellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carrageenan, acacia gum, arabic gum, tragacanth, and mixtures thereof.

Suitable gel bases and viscosity-increasing components may be selected from the group
10 comprising liquid paraffin, polyethylene, fatty oils, colloidal silica or aluminium, zinc soaps, glycerol, propylene glycol, tragacanth, carboxyvinyl polymers, magnesium-aluminium silicates, Carbopol®, hydrophilic polymers such as, e.g. starch or cellulose derivatives such as, e.g., carboxymethylcellulose, hydroxyethylcellulose and other cellulose derivatives, water-swelling hydrocolloids, carragenans, hyaluronates (e.g. hyaluronate gel optionally
15 containing sodium chloride), and alginates including propylene glycol alginate.

Typical ointment bases may be selected from the group comprising beeswax, paraffin, cetanol, cetyl palmitate, vegetable oils, sorbitan esters of fatty acids (Span), polyethylene glycols, and condensation products between sorbitan esters of fatty acids and ethylene
20 oxide, e.g. polyoxyethylene sorbitan monooleate (Tween).

Typical hydrophobic ointment bases may be selected from the group comprising paraffins, vegetable oils, animal fats, synthetic glycerides, waxes, lanolin, and liquid polyalkylsiloxanes. Typical hydrophilic ointment bases are but not limited to solid
25 macrogols (polyethylene glycols).

Suitable powder components may be selected from the group comprising alginate, collagen, lactose, powder, which is able to form a gel when applied to a wound (absorbs liquid/wound exudate).

30

Suitable diluents and disintegrating agents may be selected from the group comprising lactose, saccharose, emdex, calcium phosphates, calcium carbonate, calcium sulphate, mannitol, starches and microcrystalline cellulose.

35 Suitable binding agents may be selected from the group comprising saccharose, sorbitol, gum acacia, sodium alginate, gelatine, starches, cellulose, sodium carboxymethylcellulose, methylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone and polyethyleneglycol.

Typical wetting agents may be selected from the group comprising sodium laurylsulphate and polysorbate 80.

Suitable lubricants may be selected from the group comprising talcum, magnesium stearate, calcium stearate, silicium oxide, precinol and polyethylenglycol.

Suitable coating agents may be selected from the group comprising hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, ethylcellulose and polymethylacrylates.

10

Typical suppository bases may be selected from the group comprising oleum cacao, adeps solidus and polyethylenglycols.

The present inventor has recognised the therapeutic effect of the complexes and compositions of this invention, partly by observing the reduced inflammation of the arachidonic acid induced inflamed mouse ear upon administering the complexes and compositions. This test model is a commonly employed method for screening and evaluation of anti-inflammatory drugs.

Thus, in a broadly sense the chemical complexes or compositions provides an immunomodulating effect. Moreover, the inventor has recognised that a number of diseases or conditions with similarities in the etiology of the inflammatory reactions that are provoked in the arachidonic acid induced inflamed mouse ear may be effectively treated by the present complexes and compositions of the invention. Such diseases and conditions relate in general to those associated with hypersensitivity reactions and inflammatory reactions. In a more specific sense, the chemical complexes or compositions of the invention provides suppression of hypersensitivity reactions, suppression of inflammatory reactions, suppression of IgE mediated allergic reactions, suppression of autoimmune reactions, reduction of pain, and suppression of cancer.

30

Correspondingly, a further aspect of the invention relates to a method for immunomodulation in a mammal, such as a human, comprising the administration to said mammal an effective amount of a combination of a beta-2 adrenoceptor agonist and an aminosugar, or pharmaceutically acceptable salts thereof,

or a chemical complex comprising a beta-2 adrenoceptor agonist and an aminosugar, or pharmaceutically acceptable salts thereof.

As used herein, the term "effective amount" relates to the effective dose to be determined by a qualified practitioner, who may titrate dosages to achieve the desired response.

Factors for consideration of dose will include potency, bioavailability, desired pharmacokinetic/pharmacodynamic profiles, condition of treatment, patient-related factors (e.g. weight, health, age, etc.), presence of co-administered medications (e.g., anticoagulants), time of administration, or other factors known to a medical practitioner.

5

Moreover, further aspects of the invention relates to a method for the treatment of hypersensitivity disease or inflammation comprising the administration of the above mentioned chemical complexes or compositions of the invention to a mammal, preferentially a human.

10

As used herein, the "term treatment" relates to treatment of symptoms or prevention the relapse of symptoms in a person diagnosed with a disease related to inflammation, hypersensitivity, cancer or pain.

- 15 According to the invention, the therapeutic action of the complexes or compositions of the invention may be relevant to diseases involving hypersensitivity reactions or inflammatory reactions. Hence, the therapeutic action of the complexes or compositions of the invention may be relevant to the treatment of conditions and diseases associated with hypersensitivity reactions, such as infections (viral, bacterial, fungal, parasitic), cold and
- 20 flu, contact dermatitis, insect bites, allergic vasculitis, post-operative reactions, transplantation rejection (graft-versus-host disease), and so forth.

- A further aspect of the invention relates to the use of a complex of the invention for the treatment of autoimmune disorders. Correspondingly, the invention further relates to a
- 25 method for the treatment or prevention of autoimmune disorders comprising the administration of the chemical complexes or compositions of the invention to a mammal, preferentially a human. Typically, the autoimmune disorders may be autoimmune hepatitis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Autoimmune hemolytic anemias, Grave's disease, Myasthenia gravis, Type 1 Diabetes Mellitus, Inflammatory
- 30 myopathies, Multiple sclerosis, Hashimoto's thyroiditis, Autoimmune adrenalitis, Crohn's Disease, Ulcerative Colitis, Glomerulonephritis, Progressive Systemic Sclerosis (Scleroderma), Sjögren's Disease, Lupus Erythematosus, Primary vasculitis, Rheumatoid Arthritis, Juvenile Arthritis, Mixed Connective Tissue Disease, Psoriasis, Pemfigus, Pemfigoid, and Dermatitis Herpetiformis.

35

A still further aspect of the invention relates to a method for the treatment or prevention of an IgE mediated allergic reaction or condition comprising administration of the chemical complexes or compositions of the invention to a mammal, preferably to a human. The therapeutic action may be relevant to IgE mediated allergic reactions and conditions in

general such as asthma, eczema (e.g. atopic dermatitis), urticaria, allergic rhinitis, anaphylaxis.

Moreover, the chemical complex or composition of the present invention may be used in a method for the treatment or prevention of any condition associated with pain. The applicant proposes the hypothesis that the therapeutic action is related to immunomodulation, possibly to a suppressing effect on hypersensitivity reactions.

Still further, the chemical complexes or compositions of the invention may be employed for the treatment or prevention of cancer of any type and at any stage. The present inventor puts forward the hypothesis that the anticancer effect is due to a combination of immunomodulating and tumour-suppressing effects of the complexes and compositions of the invention.

A still further aspect of the invention relates to the use of a combination of a beta-2 adrenoceptor agonist and an aminosugar for the preparation of a medicament for the immunomodulation of a mammal, such as a human. The immunomodulation typically results in the suppression of hypersensitivity and suppression of inflammatory reactions. The immunomodulation may be associated with diseases and disorders selected from the group consisting of hypersensitivity skin disease such as atopic eczema, contact dermatitis, seborrhoeic eczema and/or psoriasis; IgE mediated allergic reactions such as asthma, allergic rhinitis or anaphylaxis; autoimmune disease such as chronic inflammatory disease, Crohn's disease, ulcerative colitis, rheumatoid arthritis, gout or osteoarthritis; pain and cancer.

Accordingly, the chemical complexes or compositions of the invention are suitable for the treatment or prevention of diseases caused by inflammation of various tissues, such as the inflammation of the prostate, in particular prostatitis.

A still further aspect of the invention relates to a process for the preparation of a complex comprising i) a beta-2 adrenoceptor agonist; and ii) an aminosugar, comprising the steps of:

- i) dissolving said beta-2 adrenoceptor and said aminosugar in a volatile solvent or a mixture of volatile solvents; and
- ii) removing said suitable solvent so as to obtain a moisture content of at the most 5% w/w.

In principle, a plethora of solvents and mixture of solvents can be used in the preparation of complexes according to the invention. Suitable solvents or mixture of solvents are those

- being substantially removed upon evaporation at room temperature, at elevated temperature, under atmospheric or reduced pressure, or upon spray drying or freeze-drying. Furthermore, solvents and mixture of solvents should be suitable for dissolving or at least partially dissolving said beta-2-adrenoceptor and said aminosugar at room
- 5 temperature or optionally upon heating. In a preferred embodiment of the invention, the beta-2 adrenoceptor and said aminosugar are fully dissolved in the suitable solvent or mixture of suitable solvents. Preferably, no traces of undissolved beta-2 adrenoceptor and said aminosugar is present in the solution.
- 10 Thus, according to the invention the volatile solvent is selected from the group consisting of water, water-miscible, volatile organic solvents and mixtures thereof. Suitable water-miscible organic solvents is selected from the group consisting of methanol, ethanol, propanol, iso-propanol, butanol, iso-butanol, tert-butanol, acetone, acetic acid, acetonitrile, ethers, chloroform and dichloromethane. Further suitable solvents relates to
- 15 organic solvents capable of both dissolving hydrophobic and hydrophilic substances, such as those organic solvents selected from the group consisting of dimethylsulfoxide and dimethylformamids. Moreover, any other azeotrope solvents is preferred.

- As stated, the process for preparation of a complex comprises removing of solvent so as to
- 20 obtain a complex that is essentially dry, in solid form and in accordance with the IUPAC definition of a chemical complex. That is to say so as to form a complex with low moisture content and/or wherein the components are loosely associated at the molecular level and mixed with each other. The moisture being residues of water and/or residues of the water miscible organic solvents. Thus, in a interesting embodiment of the invention, the moisture
- 25 content is at the most 3% w/w, preferably at the most about 2% w/w, more preferably at the most about 1% w/w, even more preferably at the most about 0.5 % w/w, most preferably at the most about 0.2 % w/w.

EXAMPLES

- 30 The following examples describe the preparation of chemical complexes of the present invention.

General method example 1-164:

- The beta-2 adrenoceptor agonist and the aminosugar derivative are dissolved in as little
- 35 solvent as possible. The solvent is removed by spray drying or freeze-drying. After the solvent is removed the complex is a white to yellowish powder.

The solvent is water:ethanol in any v/v % combination.

The complex is suitable for any type of product e.g. pharmaceutical products, dietary supplements and cosmetic formulations. Non-limiting examples of such products are tablets, capsules, ointments and lotions as described above.

- 5 Example 1 to 32: Molar ratio beta-2 adrenoceptor agonist/ aminosugar derivative 1:10000 (mol/mol).

	beta-2 adrenoceptor agonist 1 mol	Aminosugar 10000 mol
Example 1.	Salbutamol	Glucosamine
Example 2.	Bambuterol	Glucosamine HCl
Example 3.	bitolterol	Glucosamine sulfate
Example 4.	Carbuterol	Glucosamine 2 sulfate, free acid
Example 5.	Clenbuterol	Glucosamine 2 sulfate, Na ⁺ salt
Example 6.	Clorprenaline	Glucosamine 2 sulfate, K ⁺ salt
Example 7.	Dioxethedrine	N-acetylglucosamine 3,4,6 sulfate, tri Na ⁺ salt
Example 8.	Dopexamine	Galactosamine 3,6 sulfate, K ⁺ salt
Example 9.	Ephedrine	N-acetylgalactosamine
Example 10.	Epinephrine	N-acetylgalactosamine sulfate
Example 11.	Etafedrine	N-acetylglucosamine
Example 12.	Ethylnorepinephrine	Glucosamine 6 sulfate, Na ⁺ salt
Example 13.	Fenoterol	Glucosamine 3 sulfate, Na ⁺ salt
Example 14.	Formoterol	Galactosamine 3,6 sulfate, K ⁺ salt
Example 15.	Hexoprenaline	N-acetylgalactosamine
Example 16.	Isoetarine	Glucosamine HCl
Example 17.	Isoproterenol	Mannosamine HCl
Example 18.	Mabuterol	N-acetylmannosamine
Example 19.	Metaproterenol	Glucosamine sulfate
Example 20.	Methoxyphenamine	N-acetylglucosamin
Example 21.	Pirbuterol	N-acetylgalactosamine
Example 22.	Procaterol	N-acetylgalactosamine sulfate
Example 23.	Protokylol	N-acetylglucosamine
Example 24.	Reproterol	Glucosamine 6 sulfate, Na ⁺ salt
Example 25.	Rimiterol	Glucosamine 3 sulfate, Na ⁺ salt
Example 26.	Ritodrine	Galactosamine 3,6 sulfate, K ⁺ salt
Example 27.	Salbutamol	N-acetylgalactosamine
Example 28.	Salmeterol	Glucosamine HCl
Example 29.	Soterenol	Mannosamine HCl

Example 30.	Terbutaline	N-acetylmannosamine
Example 31.	Tretoquinol	Glucosamine sulfate
Example 32.	tulobuterol	N-acetylglucosamin

Example 33 to 51: Molar ratio beta-2 adrenoceptor agonist / aminosugar derivative 1:6496 (mol/mol).

	Beta-2 adrenoceptor agonist 1mol	Aminosugar 6332 mol
Example 33.	formoterol fumarate dihydrate	Glucosamine HCl
Example 34.	bambuterol HCl	Glucosamine 3 sulfate, Na ⁺ salt
Example 35.	Bitoltrol mesylate	Galactosamine 3,6 sulfate, K ⁺ salt
Example 36.	Clenbuterol HCl	N-acetylgalactosamine
Example 37.	Chlorprenaline HCl, H ₂ O	N-acetylglucosamine
Example 38.	Dopexamine 2HCl	Glucosamine sulfate
Example 39.	Isoetarine	Glucosamine HCl
Example 40.	Isoproterenol	Mannosamine HCl
Example 41.	Mabuterol HCl	N-acetylmannosamine
Example 42.	Metaproterenol	Glucosamine sulfate
Example 43.	Methoxyphenamine HCl	N-acetylglucosamin
Example 44.	Pirbuterol monoacetate	N-acetylgalactosamine
Example 45.	Procaterol	N-acetylgalactosamine sulfate
Example 46.	Protokylol	N-acetylglucosamine
Example 47.	Reproterol HCl	Glucosamine 6 sulfate, Na ⁺ salt
Example 48.	Rimiterol HBr	Glucosamine 3 sulfate, Na ⁺ salt
Example 49.	Ritodrine HCl	Galactosamine 3,6 sulfate, K ⁺ salt
Example 50.	Salbutamol sulfate	N-acetylgalactosamine
Example 51.	Salmeterol	Glucosamine HCl

5

Example 52 to 73: Molar ratio beta-2 adrenoceptor agonist / aminosugar derivative 1:832 (mol/mol).

	Beta-2 adrenoceptor agonist 1mol	Aminosugar 1500 mol
Example 52.	Soterenol	N-acetylgalactosamine
Example 53.	Terbutaline	Glucosamine HCl

	Beta-2 adrenoceptor agonist 1mol	Aminosugar 1500 mol
Example 54.	Tretoquinol HCl	Glucosamine 6 sulfate, free acid
Example 55.	Tulobuterol	Glucosamine sulfate
Example 56.	Salbutamol sulfate	Glucosamine HCl
Example 57.	Formoterol fumerate dihydrate	Glucosamin 3 sulfate, K ⁺ salt
Example 58.	Dopexamine	Galactosamine 3,6 sulfate, K ⁺ salt
Example 59.	Ephedrine	N-acetylgalactosamine
Example 60.	Epinephrine	N-acetylgalactosamine sulfate
Example 61.	Etafedrine	N-acetylglucosamine
Example 62.	Ethylnorepinephrine	Glucosamine 6 sulfate, Na ⁺ salt
Example 63.	Fenoterol HBr	Glucosamine 3 sulfate, Na ⁺ salt
Example 64.	Formoterol	Galactosamine 3,6 sulfate, K ⁺ salt
Example 65.	Isoproterenol sulfate dihydrate	Mannosamine HCl
Example 66.	Mabuterol	N-acetylmannosamine
Example 67.	Metaproterenol HCl	Glucosamine sulfate
Example 68.	Methoxyphenamine	N-acetylglucosamin
Example 69.	Salbutamol	N-acetylgalactosamine
Example 70.	Salmeterol	Glucosamine HCl
Example 71.	Soterenol	Mannosamine HCl
Example 72.	Terbutaline sulfate	N-acetylmannosamine
Example 73.	Tretoquinol	Glucosamine sulfate

Example 74 to 91: Molar ratio beta-2 adrenoceptor agonist/ aminosugar derivative 1:405 (mol/mol).

	Beta-2 adrenoceptor agonist 1mol	Aminosugar 405 mol
Example 74.	Salbutamol	N-acetylglucosamin
Example 75.	bitolterol	Galactosamine
Example 76.	Carbuterol	Glucosamine HCl
Example 77.	Clenbuterol HCl	Glucosamine sulfate
Example 78.	Clorprenaline	Galactosamine 3,6 sulfate, di Na ⁺ salt
Example 79.	Dioxethedrine	N-acetylglucosamin HCl

	Beta-2 adrenoceptor agonist 1mol	Aminosugar 405 mol
Example 80.	Ethylnorepinephrine HCl	Glucosamine 6 sulfate, Na ⁺ salt
Example 81.	Fenoterol	Glucosamine 3 sulfate, Na ⁺ salt
Example 82.	Formoterol	Galactosamine 3,6 sulfate, K ⁺ salt
Example 83.	Isoproterenol	Mannosamine HCl
Example 84.	Mabuterol HCl	N-acetylmannosamine
Example 85.	Metaproterenol HCl	Glucosamine sulfate
Example 86.	Methoxyphenamine	N-acetylglucosamin
Example 87.	Salbutamol sulfate	N-acetylgalactosamine
Example 88.	Salmeterol	Glucosamine HCl
Example 89.	Soterenol HCl	Mannosamine HCl
Example 90.	Terbutaline sulfate	N-acetylmannosamine
Example 91.	Tretoquinol	Glucosamine sulfate

Example 92 to 115: Molar ratio beta-2 adrenoceptor agonist/ aminosugar derivative 1:130 (mol/mol).

	Beta-2 adrenoceptor agonist 1mol	Aminosugar 130 mol
Example 92.	Salbutamol	Glucosamine sulfate
Example 93.	Clenbuterol	Galactosamine
Example 94.	Clorprenaline	N-acetylgalactosamine 3,6 sulfate, K ⁺ salt
Example 95.	Dioxethedrine	Glucosamine sulfate
Example 96.	Dopexamine	N-acetylglucosamine HCl
Example 97.	Ephedrine	N-acetylglucosamine 3 sulfate, free acid
Example 98.	Epinephrine	Galactosamine 4 sulfate, K ⁺ salt
Example 99.	Etafedrine	N-acetylgalactosamine 3,6 sulfate, Na ⁺ salt
Example 100.	Ethylnorepinephrine	Glucosamine 6 sulfate, K ⁺ salt
Example 101.	Fenoterol	Glucosamine 2,3 sulfate, di Na ⁺ salt
Example 102.	Formoterol fumerate dihydrate	N-acetylglucosamine HCl
Example 103.	Hexoprenaline	Glucosamine sulfate
Example 104.	Salmeterol	Glucosamine HCl
Example 105.	Soterenol	Mannosamine HCl
Example 106.	Terbutaline	N-acetylmannosamine
Example 107.	Tretoquinol	Glucosamine sulfate
Example 108.	Hexoprenaline	N-acetylgalactosamine
Example 109.	Isoetarine	Glucosamine HCl

	Beta-2 adrenoceptor agonist 1mol	Aminosugar 130 mol
Example 110.	Isoproterenol	Mannosamine HCl
Example 111.	Mabuterol	N-acetylmannosamine
Example 112.	Metaproterenol	Glucosamine sulfate
Example 113.	Methoxyphenamine	N-acetylglucosamin
Example 114.	Pirbuterol	N-acetylgalactosamine
Example 115.	Procaterol	N-acetylgalactosamine sulfate

Example 116 to 124: Molar ratio beta-2 adrenoceptor agonist/ aminosugar derivative 1:19 (mol/mol).

	Beta-2 adrenoceptor agonist 1mol	Aminosugar 19 mol
Example 116.	Salbutamol	Glucosamine sulfate
Example 117.	Salbutamol sulfate	Glucosamine 2 sulfate, K ⁺ salt
Example 118.	Bitolterol	Galactosamine
Example 119.	Carbuterol	Glucosamine
Example 120.	Clenbuterol	N-acetylgalactosamine 4 sulfate, K ⁺ salt
Example 121.	Clorprenaline	N-acetyl-glucosamine HCl
Example 122.	Tretoquinol	Galactosamine 2 sulfate, Na ⁺ salt
Example 123.	Hexoprenaline	Mannosamine HCl
Example 124.	Isoetarine	N-acetylmannosamine

5

Example 125 to 137: Molar ratio beta-2 adrenoceptor agonist/ aminosugar derivative 1:1 (mol/mol).

	Beta-2 adrenoceptor agonist 1mol	Aminosugar 1 mol
Example 125.	Bambuterol HCl	Glucosamine HCl
Example 126.	Bitolterol mesylate	N-acetyl-glucosamine
Example 127.	Salbutamol	Galactosamine sulfate
Example 128.	Formoterol fumerate dihydrate	Glucosamine 3,4,6 sulfate, free acid
Example 129.	Tretoquinol HCl	N-acetylgalactosamine HCl
Example 130.	Hexoprenaline sulfate	N-acetylgalactosamine
Example 131.	Broxaterol	Glucosamine HCl
Example 132.	Isoproterenol	Mannosamine HCl

	Beta-2 adrenoceptor agonist 1mol	Aminosugar 1 mol
Example 133.	Mabuterol	N-acetylmannosamine
Example 134.	Metaproterenol-sulfate	Glucosamine sulfate
Example 135.	Methoxyphenamine	N-acetylglucosamin
Example 136.	Pirbuterol 2HCl	N-acetylgalactosamine
Example 137.	Procaterol	N-acetylgalactosamine sulfate

Example 138 to 143: Molar ratio beta-2 adrenoceptor agonist/ aminosugar derivative 5:1 (mol/mol).

	Beta-2 adrenoceptor agonist 5mol	Aminosugar 1 mol
Example 138.	Salbutamol	Galactosamine 4 sulfate, K ⁺ salt
Example 139.	Formoterol fumarate dihydrate	N-acetylglucosamin
Example 140.	Fenoterol HBr	N-acetylgalactosamine
Example 141.	Mabuterol	Mannosamine HCl
Example 142.	Methoxyphenamine HCl	N-acetylglucosamine HCl
Example 143.	Reproterol	Glucosamine sulfate

5

Example 144 to 148: Molar ratio beta-2 adrenoceptor agonist / aminosugar derivative 50:1 (mol/mol).

	Beta-2 adrenoceptor agonist 50mol	Aminosugar 1 mol
Example 144.	Dioxethedrine	Glucosamine sulfate
Example 145.	Dopexamine 2HCl	N-acetylglucosamine
Example 146.	Ephedrine HCl	Galactosamine HCl
Example 147.	Epinephrine	N-acetylmannosamine
Example 148.	Salbutamol sulfate	N-acetylglucosamin HCl

10

Example 149 to 153: Molar ratio beta-2 adrenoceptor agonist / aminosugar derivative 500:1 (mol/mol).

	Beta-2 adrenoceptor agonist 500mol	Aminosugar 1 mol
Example 149.	Rimiterol	Glucosamine sulfate

	Beta-2 adrenoceptor agonist 500mol	Aminosugar 1 mol
Example 150.	Bitolterol mesylate	N-acetylglucosamine
Example 151.	Salbutamol	Galactosamine HCl
Example 152.	Salmeterol xinafoate	Mannosamine
Example 153.	Clenbuterol HCL	N-acetylglucosamin HCl

Example 154 to 159: Molar ratio beta-2 adrenoceptor agonist / aminosugar derivative
1000:1 (mol/mol).

	Beta-2 adrenoceptor agonist 1000mol	Aminosugar 1 mol
Example 154.	Mabuterol HCl	Glucosamine sulfate
Example 155.	Clenbuterol	N-acetylglucosamine
Example 156.	Salbutamol sulfate	Galactosamine HCl
Example 157.	Tulobuterol HCl	N-acetylgalactosamine 3,6 sulfate, di Na ⁺ salt
Example 158.	Ritodrine HCl	N-acetylglucosamin HCl
Example 159.	Protokylol	Mannosamine HCl

5 Example 160 to 164: Molar ratio beta-2 adrenoceptor agonist / aminosugar derivative
10000:1 (mol/mol).

	Beta-2 adrenoceptor agonist 10000mol	Aminosugar 1 mol
Example 160.	Pirbuterol 2HCl	Glucosamine sulfate
Example 161.	Methoxyphenamine	N-acetylglucosamine
Example 162.	salbutamol	Galactosamine HCl
Example 163.	Isoetarine	N-acetylgalactosamine 3,6 sulfate, di Na ⁺ salt
Example 164.	Fenoterol HCl	N-acetylglucosamin HCl

General method example 165-176:

- 10 A quantity of the beta-2 adrenoceptor agonist and the aminosugar derivative are transferred to a hard gelatine capsule.

Example 165 to 170: Capsule 500 mg, molar ratio beta-2 adrenoceptor agonist/
amino sugar derivative 1:1000 (mol/mol).

	Beta-2 adrenoceptor agonist 1mol	Aminosugar 1000 mol
Example 165.	Salbutamol 239.31g/mol 0.55mg	Glucosamin HCl 215.6g/mol 499.45mg
Example 166.	Salbutamol sulfate 576.7g/mol 1.3mg	N-acetylglucosamine 221.2g/mol 498.7mg
Example 167.	Formoterol fumerate dihydrate 840.91g/mol 0.7mg	Glucosamine sulfate 605.1g/mol 499.3mg
Example 168.	Formoterol 344.41g/mol 0.8mg	Galactosamine HCl 215.6g/mol 499.2mg
Example 169.	Fenoterol 303.36g/mol 0.7mg	Mannosamine HCl 215.6g/mol 499.3mg
Example 170.	Mabuterol 310.75g/mol 0.7mg	N-acetylmannosamine 221.2g/mol 499.3mg

5

Example 171 to 176: Capsule 750 mg, molar ratio beta-2 adrenoceptor agonist/
amino sugar derivative 1:53(mol/mol).

	Beta-2 adrenoceptor agonist 1mol	Aminosugar 53 mol
Example 171.	Dopexamine 356.51g/mol 22.7mg	Glucosamin HCl 215.6g/mol 727.3mg
Example 172.	Salbutamol sulfate 576.7g/mol 35.16mg	N-acetylglucosamine 221.2g/mol 714.84mg
Example 173.	Formoterol fumerate dihydrate 840.91g/mol 19.16mg	Glucosamine sulfate 605.1g/mol 730.84mg
Example 174.	Salbutamol 239.31g/mol 15.0mg	N-acetylglucosamine 221.2g/mol 735.0mg
Example 175.	Ephedrine 165.24g/mol 10.4mg	N-acetylmannosamine 221.2g/mol 739.6mg

	Beta-2 adrenoceptor agonist 1mol	Aminosugar 53 mol
Example 176.	Formoterol 344.41g/mol 21.94mg	Glucosamin HCl 215.6g/mol 728.06mg

*Example 177*Objective

- 5 The objective of this study is to assess the effect of three doses of two chemical complexes of the invention systemically administered in the arachidonic acid induced ear inflammation test in the mouse, a commonly employed method for screening and evaluation of antiinflammatory drugs. Dexamethasone was employed as reference compound.

10 Test articles and vehicle

The test articles are the complexes of the invention prepared according to example 33 and example 92 (Compound 33 and Compound 92 in the following). Compound 33, Compound 92 and dexamethasone are obtained from Astion A/S, Denmark.

15 Animals

The study was performed in female BALB/ca mice from M & B A/S, DK-8680 Ry. At start of the acclimatisation period the mice were in the weight range of 20 g (+/- 5g).

Housing

- 20 The study took place in an animal room provided with filtered air. The temperature in the room was set at 21 - 23°C and the relative humidity to $\geq 30\%$. The room was illuminated to give a cycle of 12 hours light and 12 hours darkness. Light was on from 06.00 till 18.00 h.

- The animals were housed in Macrolon type III cages (40x25x14 cm), 10 in each cage. The cages were cleaned and the bedding changed at least once a week.

Bedding

The bedding was sawdust (Tapvei 4HV) from Tapvei Oy, 73620 Korteinen, Finland.

30 Diet

A complete pelleted rodent diet "Altromin 1324" from Chr. Petersen, DK- 4100 Ringsted, was available ad libitum.

Drinking water

- 35 The animals had free access to bottles with domestic quality drinking water. The drinking water was changed daily.

Animal randomisation and allocation

On the day of arrival the animals were randomly allocated to groups of 8 mice.

5 Body weight

The animals were weighed on the day of dosing.

Procedure

10 The test substances and reference compound were administered intraperitoneally in volumes of 20 ml per kg body weight 30 minutes before application of arachidonic acid to the ear.

All groups were treated with 20 μ l arachidonic acid, 100 mg/ml in acetone, on the right ear.

15

The doses were as follows:

Drug	Dose, mg/kg
Vehicle, PBS	-, i.p.
Compound 92	1000 mg/kg, i.p.
Compound 92	300 mg/kg, i.p.
Compound 92	100 mg/kg, i.p.
Compound 33	1000 mg/kg, i.p.
Compound 33	300 mg/kg, i.p.
Compound 33	100 mg/kg, i.p.
Dexamethasone	6 mg/kg, i.p.
Dexamethasone	2 mg/kg, i.p.

20 One hour after the arachidonic acid application the mice were sacrificed, the ears cut from the tip with a punch biopsy knife (8 mm diameter) and weighed.

Mean weights and standard deviations were calculated. Relative ear oedema was assessed as the weight difference between right and left ear of each mouse expressed as percent of the left ear. Percent inhibition of the relative ear oedema compared with the vehicle
25 treated groups was calculated for the test substance and reference compound treated groups.

Clinical signs

All visible signs of ill health and any behavioural changes were recorded daily during the study. Any deviation from normal was recorded with respect to time of onset, duration and intensity.

5 Statistics

Differences in relative ear oedema between the vehicle treated groups and the test substance and reference compound treated groups were tested for significance employing a non-parametric statistical method of analysis, the Mann-Whitney U test. The required level of significance was $p < 0.05$.

- 10 All statistical analysis was performed employing the statistical software package Analyse-it v. 1.62.

RESULTS

15 Clinical signs

Arachidonic acid caused an inflammation in the right ears, which was visible after about 30 minutes. It could clearly be observed that the right ears were bright red and the left ears pale. The test articles to some extent prevented the reaction in the right ear. No test substance related adverse reactions were observed.

20

Ear oedema

The various concentrations of the test articles inhibited the relative oedema as shown in the table below:

Drug	Dose, mg per application	% Inhibition of relative ear oedema	Mann-Whitney U test
Vehicle, PBS	-, i.p.	-	-
Compound 92	1000 mg/kg, i.p.	65	$p < 0.0001$
Compound 92	300 mg/kg, i.p.	44	$p = 0.0009$
Compound 92	100 mg/kg, i.p.	14	$p = 0.0652$
Compound 33	1000 mg/kg, i.p.	79	$p = 0.0002$
Compound 33	300 mg/kg, i.p.	64	$p < 0.0001$
Compound 33	100 mg/kg, i.p.	47	$p = 0.0052$
Dexamethasone	6 mg/kg, i.p.	0	$p = 0.8359$
Dexamethasone	2 mg/kg, i.p.	0	$p = 0.6008$

25

Compound 92 and Compound 33 yielded a dose dependent and at all doses statistically significant inhibition of ear oedema. Dexamethasone, the reference compound, surprisingly did not inhibit ear oedema. This is attributed to a slower onset of action. Thus, the data imply that Compound 92 and Compound 33 have a faster onset of action than

5 dexamethasone.

CONCLUSION

The data imply that systemically administered Compound 92 and Compound 33 are potent
10 inhibitors of arachidonic acid induced ear oedema, with a faster onset of action than dexamethasone.

Example 178

15

Objective

The objective of this study is to assess the effect of a dose of a complex according to compared to the effect of the corresponding doses of the components of the complex. All compounds were systemically administered in the arachidonic acid induced ear
20 inflammation test in the mouse, a commonly employed method for screening and evaluation of antiinflammatory drugs. Methylprednisolone was employed as reference compound.

Test articles and vehicle

25 The test articles are the complex of the invention prepared according to example 92 (Compound 92 in the following) and its components salbutamol and glucosamine sulfate. The substances were obtained from Astion A/S, Denmark.

Animals

30 The study was performed in female BALB/ca mice from M & B A/S, DK-8680 Ry. At start of the acclimatisation period the mice were in the weight range of 20 g (+/- 5g).

Housing

The study took place in an animal room provided with filtered air. The temperature in the
35 room was set at 21 - 23°C and the relative humidity to ≥30%. The room was illuminated to give a cycle of 12 hours light and 12 hours darkness. Light was on from 06.00 till 18.00 h.

The animals were housed in Macrolon type III cages (40x25x14 cm), 10 in each cage. The cages were cleaned and the bedding changed at least once a week.

Bedding

The bedding was sawdust (Tapvei 4HV) from Tapvei Oy, 73620 Kortteinen, Finland.

5 Diet

A complete pelleted rodent diet "Altromin 1324" from Chr. Petersen, DK- 4100 Ringsted, was available ad libitum.

Drinking water

- 10 The animals had free access to bottles with domestic quality drinking water. The drinking water was changed daily.

Animal randomisation and allocation

On the day of arrival the animals were randomly allocated to groups of 10 mice.

15

Body weight

The animals were weighed on the day of dosing and termination of the study.

Procedure

- 20 The test substances and reference compound were administered intraperitoneally in volumes of 20 ml per kg body weight 30 minutes before application of arachidonic acid to the ear.

All groups were treated with 20 µl arachidonic acid, 100 mg/ml in acetone, on the right

25 ear.

The doses were as follows:

Drug	Dose, mg/kg
Vehicle, PBS	-, i.p.
Compound 92	1000 mg/kg, i.p.
Glucosamine sulfate	997 mg/kg, i.p.
Salbutamol	3.0 mg/kg, i.p.
Methylprednisolone	30 mg/kg, i.p.

- 30 One hour after the arachidonic acid application the mice were sacrificed, the ears cut from the tip with a punch biopsy knife (8 mm diameter) and weighed.

Mean weights and standard deviations were calculated. Relative ear oedema was assessed as the weight difference between right and left ear of each mouse expressed as percent of the left ear. Percent inhibition of the relative ear oedema compared with the vehicle treated groups was calculated for the test substance and reference compound treated 5 groups.

Clinical signs

All visible signs of ill health and any behavioural changes were recorded daily during the study. Any deviation from normal was recorded with respect to time of onset, duration and 10 intensity.

Statistics

Differences in relative ear oedema between the vehicle treated group and the other groups were tested for significance employing a non-parametric statistical method of analysis, the 15 Mann-Whitney U test. The required level of significance will be $p < 0.05$. Similarly, the difference between the compound 92 treated group and the groups treated with the corresponding amounts of salbutamol and glucosamine sulfate respectively, were tested for significance to establish whether Compound 92 displays a significantly better effect than its components at the dose they occur in Compound 92. All statistical analysis 20 was performed employing the statistical software package Analyse-it v. 1.62.

RESULTS

25 Clinical signs

Arachidonic acid caused an inflammation in the right ears, which was visible after about 30 minutes. It could clearly be observed that the right ears were bright red and the left ears pale. The test articles to some extent prevented the reaction in the right ear. No test substance related adverse reactions were observed.

30

Ear oedema

The various concentrations of the test articles inhibited the relative oedema as shown in the table below:

Drug	Dose, mg/kg	% Inhibition of relative ear oedema	Mann-Whitney U test
Vehicle, PBS	-	-	-

Compound 92	1000 mg/kg	73	$p < 0.0001$
Glucosamine sulfate	997 mg/kg	9	$p = 0.1399$
Salbutamol	3.0 mg/kg	55	$p < 0.0001$
Methylprednisolone	30 mg/kg	55	$p < 0.0001$

- Compound 92 yielded a statistically significant inhibition of ear oedema. Glucosamine sulfate inhibited ear oedema mildly, and not statistically significantly, while Salbutamol inhibited ear oedema significantly. In the group receiving Compound 92 the relative ear oedema was 71% and 40% lower than in the groups receiving the corresponding doses of glucosamine sulfate and salbutamol, respectively. These differences were statistically significant, $p < 0.0001$ and $p = 0.0076$, respectively, and since Compound 92 reached a higher level of inhibition than the sum of inhibition of the corresponding doses of glucosamine sulfate and salbutamol, the data imply a synergistic effect.
- Compound 92 yielded a 41% lower ear oedema than methylprednisolone and this difference was significant ($p = 0.0021$).

CONCLUSION

- The data imply that systemically administered Compound 92 is a potent inhibitor of arachidonic acid induced ear oedema and that the surprisingly strong inhibition is obtained through a synergistic effect between the components of the complex.

20 *Example 179*

- A woman (70 years old) had been suffering from significant muscular pain for 6 years and had for periods been under treatment with different analgesics including ibuprofen and celecoxib with limited success. The last year she had continuously been taking a supplement of glucosamine sulfate, 1500 mg a day, but only obtained a small improvement of her symptoms. She was then treated with the complex of the invention disclosed in example 56 (1500 mg/day) instead of glucosamine sulfate. After two days she could feel a significant improvement compared to taking the aminosugar alone. After two weeks she was symptom free for the first time in 6 years, which persisted for another 6 weeks of treatment, where after the treatment was terminated. No adverse effects were observed.

Example 180

- A male, 68 years had been suffering from osteoarthritis of the knees for 8 years and had for periods been under treatment with different analgesics including diclofenac codeine and

rofecoxib with limited success. He had also tried the recommended dose of glucosamine in different formulations, but with very limited effect. He was then treated with the complex of the invention disclosed in example 56 (1500 mg/day). After four days he experienced a significant improvement of his major symptom pain in the knees in relation to walking. The
5 improvement continued and after two weeks he was completely symptom free. The improvement persisted for the entire treatment period of 10 weeks, where after the treatment was terminated. No adverse effects were observed.

CLAIMS

1. A chemical complex comprising:

i) a beta-2 adrenoceptor agonist; and

5 ii) an aminosugar.

2. A chemical complex according to claim 1, wherein the beta-2 adrenoceptor agonist is selected from the group consisting of bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, clorprenaline, dioxethedrine, dopexamine, ephedrine, epinephrine, etafedrine, 10 ethylnorepinephrine, fenoterol, formoterol, hexoprenaline, isoetarine, isoproterenol, mabuterol, metaproterenol, methoxyphenamine orcliprenaline, pirbuterol, procaterol, protokylol, reproterol, rimiterol, ritodrine, salbutamol (albuterol), salmeterol, soterenol, terbutaline, tretoquinol, tulobuterol, derivatives and salts thereof.

15 3. The chemical complex according to any one of claims 1 or 2, wherein said aminosugar is an aminosugar derivative selected from the group consisting of an aminosugar derivative of a monosaccharide, aminosugar derivative of a di or oligosaccharide, aminosugar derivative of a polysaccharide, derivatives and salts thereof.

20 4. The chemical complex according to claim 3, wherein said aminosugar derivative has a molecular weight of less than 5000 Daltons, preferably less than 4000 Daltons, more preferably less than 3000 Daltons.

25 5. The chemical complex according to any one of claims 1 or 2, wherein said aminosugar is an aminosugar derivative of a monosaccharide selected from the group consisting of glucosamine, galactosamine, mannosamine, derivatives and salts thereof.

30 6. The chemical complex according to any one of claims 2 or 3, wherein said aminosugar derivative comprises a saccharide selected from the group consisting of glucosamine, galactosamine and mannosamine.

7. The chemical complex according to any one of preceding claims, wherein said aminosugar is N-acetylated.

35 8. The chemical complex according to any one of preceding claims, wherein said aminosugar is a sulfate salt or a hydrochloride salt.

9. The chemical complex according to any one of preceding claims, wherein the aminosugar is a glucosamine sulfate.

10. The chemical complex according to any one of preceding claims, wherein the beta-2
5 adrenoceptor agonist and the aminosugar are present in a molar ratio of between about 1:10000 to 10000:1, preferably about 1:1000 to 1000:1, such as about 1:100 to 100:1, such as about 1:10 to 10:1, also about 1:5 to 5:1, such as about 1:2 to 2:1.

11. A composition comprising:

- 10 i) a beta-2 adrenoceptor agonist;
ii) an aminosugar; and optionally
iii) one or more acceptable excipients or carriers.

12. The composition according to claim 11, wherein the beta-2 adrenoceptor agonist is
15 selected from the group consisting of bambuterol, bitolterol, carbuterol, clenbuterol, clorprenaline, dioxethedrine, dopexamine, ephedrine, epinephrine, etafedrine, ethylnorepinephrine, fenoterol, formoterol, hexoprenaline, isoetarine, isoproterenol, mabuterol, metaproterenol, methoxyphenamine, pirbuterol, procaterol, protokylol, reproterol, rimiterol, ritodrine, salbutamol (albuterol), salmeterol, soterenol, terbutaline,
20 tretoquinol, tulobuterol, derivatives and salts thereof.

13. The composition according to any one of claims 11 or 12, wherein said aminosugar is an aminosugar derivative selected from the group consisting of an aminosugar derivative of a monosaccharide, aminosugar derivative of a di or oligosaccharide, aminosugar
25 derivative of a polysaccharide, derivatives and salts thereof.

14. The composition according to claim 13, wherein said aminosugar derivative has a molecular weight of less than 5000 Daltons, preferably less than 4000 Daltons, more preferably less than 3000 Daltons.

30

15. The composition according to any one of claims 11 or 12, wherein said aminosugar is an aminosugar derivative of a monosaccharide selected from the group consisting of glucosamine, galactosamine, mannosamine, derivatives and salts thereof.

35 16. The composition according to any one of claims 12 or 13, wherein said aminosugar derivative comprises a saccharide selected from the group consisting of glucosamine, galactosamine and mannosamine.

17. The composition according to any one of claims 11 to 16, wherein said aminosugar is N-acetylated.

18. The composition according to any one of claims 11 to 17, wherein said aminosugar is a sulfate salt or a hydrochloride salt.

19. The composition according to one of claims 11 to 18, wherein the aminosugar is a glucosamine sulfate.

20. The composition according to any one of claims 11 to 19, wherein the beta-2 adrenoceptor agonist and the aminosugar are present in a molar ratio of between about 1:10000 to 10000:1, preferably about 1:1000 to 1000:1, such as about 1:100 to 100:1, such as about 1:10 to 10:1, also about 1:5 to 5:1, such as about 1:2 to 2:1.

21. The composition according to claim 11, comprising a complex comprising the beta-2 adrenoceptor agonist and the aminosugar.

22. The composition according to any one of claims 8 to 13 further comprising one or more therapeutically active agents other than a beta-2 adrenoceptor agonist and the aminosugar.

23. The composition according to any one of claims 8 to 14 in a form selected from the group consisting of oral formulation, topical formulation, transdermal formulation, and parenteral formulation.

24. Use of a combination of a beta-2 adrenoceptor agonist and an aminosugar for the preparation of a medicament for the immunomodulation of a mammal, such as a human.

25. The use according to claim 24, wherein the immunomodulation is treatment of hypersensitivity and/or inflammatory reactions.

26. The use according to claim 25, wherein the immunomodulation is associated with diseases and disorders selected from the group consisting of hypersensitivity skin disease, atopic eczema, contact dermatitis, seborrhoeic eczema, psoriasis, IgE mediated allergic reactions, asthma, allergic rhinitis, anaphylaxis, autoimmune disease, chronic inflammatory disease, Crohn's disease, ulcerative colitis, rheumatoid arthritis, gout, osteoarthritis, pain and cancer.

27. The use according to any one of claims 24 to 26, wherein the medicament comprises a composition as defined by any one of claims 11 to 22.

28. The use according to any one of claims 24 to 26, wherein the medicament comprises a
5 chemical complex as defined in any one of claims 1 to 10.

29. The use according to any one of claims 24 to 28, wherein the beta-2 adrenoceptor agonist and the aminosugar are together comprised in a single formulation or are each individually comprised in separate formulations.

10

30. The use according to any one of claims 24 to 29, wherein the medicament is in a form selected from the group consisting of oral formulation, topical formulation, transdermal formulation, and parenteral formulation.

15 31. The use according any one of claims 24 to 30, wherein the medicament further comprises one or more therapeutically active agents.

32. A method for immunomodulation in a mammal, such as a human, comprising the administration to said mammal of a combination of a beta-2 adrenoceptor agonist and an
20 aminosugar, or pharmaceutically acceptable salts thereof,
or a chemical complex comprising a beta-2 adrenoceptor agonist and an aminosugar, or pharmaceutically acceptable salts thereof.

33. The method according to claim 28 for the suppression of hypersensitivity and/or
25 inflammatory reaction in a mammal, such as a human, comprising the administration of a combination of a beta-2 adrenoceptor agonist and an aminosugar, or pharmaceutically acceptable salts thereof, or a chemical complex comprising said combination or said salts to said mammal.

30 34. The method according to claim 32 for the treatment or prevention of hypersensitivity skin disease in a mammal, such as a human, comprising the administration of a combination of a beta-2 adrenoceptor agonist and an aminosugar, or pharmaceutically acceptable salts thereof, or a chemical complex comprising said combination or said salts to said mammal.

35

35. The method according to claim 32 for the treatment or prevention of atopic eczema, contact dermatitis, seborrhoeic eczema and/or psoriasis in a mammal, such as a human, comprising the administration of a combination of a beta-2 adrenoceptor agonist and an

aminosugar, or pharmaceutically acceptable salts thereof, or a chemical complex comprising said combination or said salts to said mammal.

36. The method according to claim 32 for the treatment or prevention of IgE mediated
5 allergic reaction and/or condition in a mammal, such as a human, comprising the administration of a combination of a beta-2 adrenoceptor agonist and an aminosugar, or pharmaceutically acceptable salts thereof, or a chemical complex comprising said combination or said salts to said mammal.
- 10 37. The method according to claim 32 for the treatment or prevention of asthma, allergic rhinitis, and/or anaphylaxis in a mammal, such as a human, comprising the administration of a combination of a beta-2 adrenoceptor agonist and an aminosugar, or pharmaceutically acceptable salts thereof, or a chemical complex comprising said combination or said salts to said mammal.
- 15 38. The method according to claim 32 for the treatment or prevention of autoimmune disease and/or chronic inflammatory disease in a mammal, such as a human, comprising the administration of a combination of a beta-2 adrenoceptor agonist and an aminosugar, or pharmaceutically acceptable salts thereof, or a chemical complex comprising said
20 combination or said salts to said mammal.
39. The method according to claim 32 for the treatment or prevention of diabetes, Crohn's disease, ulcerative colitis, rheumatoid arthritis, gout or osteoarthritis in a mammal, such as a human, comprising the administration of a combination of a beta-2 adrenoceptor
25 agonist and an aminosugar, or pharmaceutically acceptable salts thereof, or a chemical complex comprising said combination or said salts to said mammal.
40. The method according to claim 32 for the alleviation of pain in a mammal, such as a human, comprising the administration of a combination of a beta-2 adrenoceptor agonist
30 and an aminosugar, or pharmaceutically acceptable salts thereof, or a chemical complex comprising said combination or said salts to said mammal.
41. The method according to claim 32 for the treatment or prevention of cancer in a mammal, such as a human, comprising the administration of a combination of a beta-2
35 adrenoceptor agonist and an aminosugar, or pharmaceutically acceptable salts thereof, or a chemical complex comprising said combination or said salts to said mammal.
42. The method according to claim 32, wherein the combination of a beta-2 adrenoceptor agonist and an aminosugar is a chemical complex as defined in claims 1 to 10.

43. The method according to claim 32, wherein the combination of a beta-2 adrenoceptor agonist and an aminosugar is a composition as defined in any one of claims 11 to 23.

5 44. The method according to claims 32, wherein the combination of a beta-2 adrenoceptor agonist and an aminosugar, or pharmaceutically acceptable salts thereof, are together comprised in a single formulation or are each individually comprised in separate formulations.

10 45. The method according to claim 32, wherein the combination of a beta-2 adrenoceptor agonist and an aminosugar is administered by means of oral, topical, transdermal, or parenteral administration, or combinations thereof.

46. The method according to claim 39, wherein the separate formulations are administered
15 in a simultaneous or non-simultaneous manner.

47. The method according to claim 46, wherein the separate formulations further comprises one or more therapeutically active substances.

20 48. The method according to any one of claim 44, wherein the combination of a beta-2 adrenoceptor agonist and an aminosugar are together comprised in a single formulation.

49. The method according to claim 48, wherein the single formulation further comprises one or more therapeutically active substances.

25

50. A process for the preparation of a complex comprising i) a beta-2 adrenoceptor agonist; and ii) an aminosugar, comprising the steps of:

i) dissolving said beta-2 adrenoceptor and said aminosugar in a volatile solvent or a mixture of volatile solvents; and

30 ii) removing said suitable solvent so as to obtain a moisture content of at the most 5% w/w.

51. The process according to claim 50, wherein the volatile solvent is selected from the group consisting of water, water-miscible volatile organic solvents and mixtures thereof.

35

52. The process according to any one of claims 50 or 51, wherein the solvent is removed by spray drying or freeze-drying.

53. The process according to to any one of claims 50 to 52 , wherein the moisture content is at the most 3% w/w, preferably at the most about 2% w/w, more preferably at the most about 1% w/w, even more preferably at the most about 0.5 % w/w, most preferably at the most about 0.2 % w/w.

INTERNATIONAL SEARCH REPORT

PCT/DK 03/00263

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/726 A61K45/06 A61P29/00 //(A61K31/726,31:135),
(A61K31/726,31:167)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, BIOSIS, EMBASE, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 609 042 A (SEIKAGAKU KOGYO CO LTD) 3 August 1994 (1994-08-03) cited in the application * col.4, 1.44-53; col.5, 1.43-44; col.8, 1.2-6; claims 1-10 *	1-23, 50-53
Y	GABY A R: "NATURAL TREATMENTS FOR OSTEOARTHRITIS" ALTERNATIVE MEDICINE REVIEW, THORNE RESEARCH INC., SANDPOINT,, US, vol. 4, no. 5, 1999, pages 330-341, XP000992206 ISSN: 1089-5159 cited in the application * p.332-5, "Glucosamine sulfate", "Chondroitin sulfate" and "Glucosamine sulfate vs. Chondroitin" * --- -/-	1-49

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

S document member of the same patent family

Date of the actual completion of the international search

13 June 2003

Date of mailing of the international search report

30/06/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Uiber, P

INTERNATIONAL SEARCH REPORT

PCT/DK 03/00263

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6 046 179 A (FRENCH IAN W ET AL) 4 April 2000 (2000-04-04) cited in the application * claims 1-10 and 18 * ---	1-49
Y	WO 98 48816 A (NUTRAMAX LAB INC) 5 November 1998 (1998-11-05) cited in the application * p.1, 120-30; claims 1-28 * ---	1-49
Y	WO 95 19336 A (IOVIS BIOMEDICAL AND PHARMACEU ;BRON JAN (NL); STERK GEERT JAN (NL) 20 July 1995 (1995-07-20) cited in the application * p.15, 3rd par.-p.16, 1st full par. * -----	1-49

INTERNATIONAL SEARCH REPORT

PCT/DK 03/00263

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0609042	A	03-08-1994	JP 3390477 B2	24-03-2003
			JP 6219938 A	09-08-1994
			CA 2114243 A1	26-07-1994
			DE 69411604 D1	20-08-1998
			DE 69411604 T2	15-04-1999
			EP 0609042 A1	03-08-1994
			US 5814621 A	29-09-1998
US 6046179	A	04-04-2000	AU 2709299 A	08-11-1999
			WO 9953929 A1	28-10-1999
			CZ 20003846 A3	13-03-2002
			EP 1071432 A1	31-01-2001
			HU 0101514 A2	28-11-2001
			JP 2002512195 T	23-04-2002
			NO 20005223 A	20-11-2000
			PL 343634 A1	27-08-2001
WO 9848816	A	05-11-1998	US 6255295 B1	03-07-2001
			AU 747595 B2	16-05-2002
			AU 6973398 A	24-11-1998
			EP 0979090 A1	16-02-2000
			NZ 500025 A	01-03-2002
			WO 9848816 A1	05-11-1998
WO 9519336	A	20-07-1995	AU 1533495 A	01-08-1995
			WO 9519336 A1	20-07-1995

CORRECTED
VERSION

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

10/512029

RECEIVED

02 AUG 2004

WIPO

PCT

Applicant's or agent's file reference 32174PC01	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/PEA/416)	
International application No. PCT/DK 03/00263	International filing date (day/month/year) 22.04.2003	Priority date (day/month/year) 19.04.2002
International Patent Classification (IPC) or both national classification and IPC A61K31/726		
Applicant ASTION DEVELOPMENT A/S et al.		



1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 4 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 5 sheets.

3. This report contains indications relating to the following items:

I ☒ Basis of the opinion
II ☐ Priority
III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
IV ☐ Lack of unity of invention
V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
VI ☐ Certain documents cited
VII ☐ Certain defects in the international application
VIII ☐ Certain observations on the international application

Date of submission of the demand 19.11.2003	Date of completion of this report 21.07.2004
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized Officer Uiber, P Telephone No. +49 89 2399-8474 

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. **PCT/DK 03/00263**

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, Pages

1-34 as originally filed

Claims, Numbers

1-41 filed with telefax on 14.07.2004

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
☐ the language of publication of the international application (under Rule 48.3(b)).
☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
☐ filed together with the international application in computer readable form.
☐ furnished subsequently to this Authority in written form.
☐ furnished subsequently to this Authority in computer readable form.
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/DK 03/00263

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application,

☒ claims Nos. 26-41

because:

☒ the said international application, or the said claims Nos. 26-41 (IA) relate to the following subject matter which does not require an international preliminary examination (specify):

see separate sheet

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the Standard.

☐ the computer readable form has not been furnished or does not comply with the Standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	1-41
	No: Claims	
Inventive step (IS)	Yes: Claims	1-41
	No: Claims	
Industrial applicability (IA)	Yes: Claims	1-41
	No: Claims	26-41

2. Citations and explanations

see separate sheet

SECTION III

- 1). Claims 26-41 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Art. 34(4)(a)(i) PCT).

SECTION V

- 2). For the assessment of the present claims 26-41 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.
- 3). The following documents (D1-D5) are referred to in this written opinion; the numbering results from the order of citations found in the Search Report and it will be adhered to in the rest of the procedure. It will be made reference to the cited passage(s) for each citation unless otherwise specified.
- 4). In view of the restriction in scope of claim 1, its subject-matter is novel over any of D1-D5 (Art. 33(2) PCT). D1 does not specify the derivatization of the aminosugar as presently claimed.
- 5). D1 which discloses the similar complex and compositions containing it, was concerned with the improved stability of the thus resulting composition. It is not concerned with the immunostimulation. The remaining documents D2-D5 already report the effectiveness of either the beta-2 adrenoreceptor agonist or said aminosugar in various inflammatory disorders, however taking separately. The problem posed in the present application can be seen as providing a new therapy in the treatment of immune-related disorders. The solution, according to the Applicant, was the use of said combination as stated in claim 1. Surprisingly, the Applicant has evidenced that such combinations achieve a synergistic activity (see Table on page 29). The skilled man could not have derived said effect from the prior art, accordingly, the subject matter of claim 1 involves an inventive step over the available cited prior art, D1-D5 (Ar. 33(3) PCT).
- 6). Items 4 and 5 also apply to claims 2-41.

1

CLAIMS

(AMENDED AFTER TELEPHONE INTERVIEW)

1. A chemical complex comprising:

5

- i) a beta-2 adrenoceptor agonist; and
- ii) an aminosugar selected from the group consisting of glucosamine, mannosamine, salts and derivatives thereof, wherein the derivatives thereof is selected from the group consisting of derivatives wherein the amino group and/or hydroxyl group of the

10

aminosugar is alkylated, arylated or acylated, and wherein the anomeric, 2-, 3-, 4-, or 6-position is sulphated or phosphorylated.

2. A chemical complex according to claim 1, wherein the beta-2 adrenoceptor agonist is selected from the group consisting of bambuterol, bitolterol, broxaterol, carbuterol,

15

clenbuterol, clorprenaline, dioxethedrine, dopexamine, ephedrine, epinephrine, etafedrine, ethylnorepinephrine, fenoterol, formoterol, hexoprenaline, isoetarine, isoproterenol, mabuterol, metaproterenol, methoxyphenamine orciprenaline, pirbuterol, procaterol, protokylol, reproterol, rimiterol, ritodrine, salbutamol (albuterol), salmeterol, soterenol, terbutaline, tretoquinol, tulobuterol, derivatives and salts thereof.

20

3. The chemical complex according to any one of preceding claims, wherein the aminosugar is glucosamine hydrochloride or glucosamine sulfate.

4. The chemical complex according to any one of preceding claims, wherein the beta-2

25

adrenoceptor agonist is salbutamol sulfate, terbutaline sulfate or formoterol fumarate dihydrate.

5. A composition comprising:

i) a beta-2 adrenoceptor agonist;

30

ii) an aminosugar selected from the group consisting of glucosamine, mannosamine, salts and derivatives thereof, wherein the derivatives thereof is selected from the group consisting of wherein the amino group and/or hydroxyl group of the aminosugar is alkylated, arylated or acylated, and wherein the anomeric, 2-, 3-, 4-, or 6- position is sulphated or phosphorylated; and

35

iii) one or more acceptable excipients or carriers.

6. The composition according to claim 5, wherein the beta-2 adrenoceptor agonist is selected from the group consisting of bambuterol, bitolterol, carbuterol, clenbuterol, clorprenaline, dioxethedrine, dopexamine, ephedrine, epinephrine, etafedrine,

40

ethylnorepinephrine, fenoterol, formoterol, hexoprenaline, isoetarine, isoproterenol, mabuterol, metaproterenol, methoxyphenamine, pirbuterol, procaterol, protokylol, reproterol, rimiterol, ritodrine, salbutamol (albuterol), salmeterol, soterenol, terbutaline, tretoquinol, tulobuterol, derivatives and salts thereof.

AMENDED SHEET

2

7. The composition according to any one of claims 5 or 6, wherein the aminosugar is glucosamine hydrochloride or glucosamine sulfate.
- 5 8. The composition according to any one of claims 5 to 8, wherein the beta-2 adrenoceptor agonist is salbutamol sulfate, terbutaline sulfate or formoterol fumarate dihydrate.
9. The composition according to claim 5, wherein the beta-2 adrenoceptor agonist and the aminosugar is in the form of a chemical complex as defined in any one claims 1-4.
- 10 10. The composition according to any one of claims 5 to 10 further comprising one or more therapeutically active agents other than a beta-2 adrenoceptor agonist and the aminosugar.
- 15 11. The composition according to any one of claims 5 to 10 in a form selected from the group consisting of oral formulation, topical formulation, transdermal formulation, and parenteral formulation.
12. Use of a combination of a beta-2 adrenoceptor agonist and an aminosugar for the
- 20 preparation of a medicament for the suppression of hypersensitivity and/or inflammatory reactions in a mammal, the aminosugar being selected from the group consisting of glucosamine, mannosamine, salts and derivatives thereof, wherein the derivatives thereof is selected from the group consisting of wherein the amino group and/or hydroxyl group of the aminosugar is alkylated, arylated or acylated, and wherein the anomeric, 2-, 3-, 4-, or
- 25 6- position is sulphated or phosphorylated.
13. The use according to claim 12, for the preparation of a medicament for treating a hypersensitivity skin disease
- 30 14. The use according to claim 13, wherein the hypersensitivity skin disease is selected from the group consisting of atopic eczema, contact dermatitis, seborrhoeic eczema and psoriasis.
15. The use according to claim 14, for the preparation of a medicament for the treatment
- 35 of contact dermatitis or psoriasis.
16. The use according to claim 12, for the preparation of a medicament for the treatment of an autoimmune disease.
- 40 17. The use according to claim 16, wherein the autoimmune disease is selected from the group consisting of autoimmune hepatitis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Autoimmune hemolytic anemias, Grave's disease, Myasthenia gravis, Type 1 Diabetes Mellitus, Inflammatory myopathies, Multiple sclerosis, Hashimoto's thyroiditis, Autoimmune adrenalitis, Crohn's Disease, Ulcerative Colitis, Glomerulonephritis,

AMENDED SHEET

3

Progressive Systemic Sclerosis (Scleroderma), Sjögren's Disease, Lupus Erythematosus, Primary vasculitis, Rheumatoid Arthritis, Juvenile Arthritis, Mixed Connective Tissue Disease, Psoriasis, Pemfigus, Pemfigoid, and Dermatitis Herpetiformis.

- 5 18. The use according to claim 16, wherein the autoimmune disease is selected from the group consisting of diabetes, Crohn's disease, ulcerative colitis, rheumatoid arthritis, multiple sclerosis, gout and osteoarthritis.
19. The use according to claim 12, for the preparation of a medicament for the treatment
10 of IgE-mediated reactions.
20. The use according to claim 19, wherein for the preparation of a medicament for the treatment of asthma, allergic rhinitis, and/or anaphylaxis.
- 15 21. The use according to any one of claims 12 to 20, wherein the medicament comprises a composition as defined by any one of claims 5 to 11.
22. The use according to any one of claims 12 to 20, wherein the medicament comprises a chemical complex as defined in any one of claims 1 to 4.
- 20 23. The use according to any one of claims 12 to 22, wherein the beta-2 adrenoceptor agonist and the aminosugar are together comprised in a single formulation or are each individually comprised in separate formulations.
- 25 24. The use according to any one of claims 12 to 23, wherein the medicament is in a form selected from the group consisting of oral formulation, topical formulation, transdermal formulation, and parenteral formulation.
25. The use according to any one of claims 12 to 24, wherein the mammal is a human.
- 30 26. A method for the suppression of hypersensitivity and/or inflammatory reactions in a mammal, comprising the administration to said mammal of a combination of a beta-2 adrenoceptor agonist and an aminosugar, or pharmaceutically acceptable salts thereof, the aminosugar being selected from the group consisting of glucosamine, mannosamine, salts and derivatives thereof, wherein the derivatives thereof is selected from the group
35 consisting of wherein the amino group and/or hydroxyl group of the aminosugar is alkylated, arylated or acylated, and wherein the anomeric, 2-, 3-, 4-, or 6- position is sulphated or phosphorylated.
- 40 27. The method according to claim 26, for the treatment or prevention of hypersensitivity skin disease in a mammal.

AMENDED SHEET

4

28. The method according to claim 27, for the treatment or prevention of atopic eczema, contact dermatitis, seborrhoic eczema and/or psoriasis.
29. The method according to claim 27, for the treatment or prevention of contact
5 dermatitis or psoriasis.
30. The method according to claim 26 for the treatment or prevention of IgE mediated allergic reaction and/or condition.
- 10 31. The method according to claim 30, for the treatment or prevention of asthma, allergic rhinitis, and/or anaphylaxis .
32. The method according to claim 26 for the treatment or prevention of autoimmune disease and/or chronic inflammatory.
15
33. The method according to claim 32, for the treatment of autoimmune hepatitis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Autoimmune hemolytic anemias, Grave's disease, Myasthenia gravis, Type 1 Diabetes Mellitus, Inflammatory myopathies, Multiple sclerosis, Hashimoto's thyroiditis, Autoimmune adrenalitis, Crohn's Disease, Ulcerative
20 Colitis, Glomerulonephritis, Progressive Systemic Sclerosis (Scleroderma), Sjögren's Disease, Lupus Erythematosus, Primary vasculitis, Rheumatoid Arthritis, Juvenile Arthritis, Mixed Connective Tissue Disease, Psoriasis, Pemfigus, Pemfigoid or Dermatitis Herpetiformis.
- 25 34. The method according to claim 33, for the treatment or prevention of diabetes, Crohn's disease, ulcerative colitis, rheumatoid arthritis, multiple sclerosis, gout or osteoarthritis.
35. The method according to any one of claims 26 to 34, wherein the mammal is a human.
- 30 36. The method according to claim 26, wherein the combination of the beta-2 adrenoceptor agonist and the aminosugar is a chemical complex as defined in claims 1 to 4.
- 35 37. The method according to claim 26, wherein the combination of a beta-2 adrenoceptor agonist and the aminosugar is a composition as defined in any one of claims 5 to 11.
- 40 38. The method according to claim 26, wherein the combination of a beta-2 adrenoceptor agonist and an aminosugar, or pharmaceutically acceptable salts thereof, are together comprised in a single formulation or are each individually comprised in separate formulations.
39. The method according to claim 26, wherein the combination of a beta-2 adrenoceptor agonist and an aminosugar is administered by means of oral, topical, transdermal, or parenteral administration, or combinations thereof.

AMENDED SHEET

5

40. The method according to claim 38, wherein the separate formulations are administered in a simultaneous or non-simultaneous manner.

- 5 41. The method according to claim 26, further comprising administering one or more therapeutically active substances other than the said beta-2 adrenoceptor agonist and said aminosugar.

AMENDED SHEET